Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom
Meronem IV 1g.
| Pharmaceutical Form |
|---|
|
Powder for solution for injection or infusion. A white to light yellow powder. |
Meronem IV 1 g.
Each vial contains meropenem trihydrate equivalent to 1 g anhydrous meropenem.
Excipients with known effect: Each 1 g vial contains 208 mg sodium carbonate which equates to approximately 4 mEq of sodium (approximately 90 mg).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Meropenem |
Meropenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs). |
| List of Excipients |
|---|
|
Meronem 1 g: Anhydrous sodium carbonate |
Meronem 1 g: 1348 mg powder in a 30 ml Type 1 glass vial with stopper (grey halobutilic rubber with an aluminium cap).
The medicinal product is supplied in pack sizes of 1 or 10 vials.
Not all pack sizes may be marketed.
Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom
Meronem 1 g: PL 00057/1536
09 February 2009
| Drug | Countries | |
|---|---|---|
| MERONEM | Brazil, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Poland, Singapore, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
